Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
TPST

TPST - Tempest Therapeutics Inc. Stock Price, Fair Value and News

$1.26+0.01 (+0.80%)
Market Closed as of 12 Jun 2026, 04:00 pm ET

Price Targets

TPST Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TPST Price Action

Last 7 days

-0.8%

Last 30 days

-31.5%

Last 90 days

-44.2%

Trailing 12 Months

-82.3%

TPST RSI Chart

TPST Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TPST Valuation

Market Cap

18.1M

Price/Earnings (Trailing)

-0.42

Price/Sales (Trailing)

304.81

EV/EBITDA

-0.83

Price/Free Cashflow

-0.69

TPST Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

TPST Fundamentals

TPST Revenue

Revenue (TTM)

72.0K

TPST Earnings

Earnings (TTM)

-43.1M

Earnings Growth (Yr)

-155.03%

Earnings Growth (Qtr)

-588.78%

TPST Profitability

Operating Margin

-494.44%

EBT Margin

-40618.75%

Return on Equity

-5.2K%

Return on Assets

-400.99%

Free Cashflow Yield

-145.97%

TPST Investor Care

Shares Dilution (1Y)

307.55%

Diluted EPS (TTM)

-5.85

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20220000
202170.0K18.0K72.0K0
20200212.0K148.0K0
2018298.5K295.5K294.5K0
2017570.0K465.0K324.0K294.5K
2016408.0K567.0K689.0K653.0K
2015000277.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Tempest Therapeutics Inc.

TPST
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
 CEO
 WEBSITEtempesttx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES19

Tempest Therapeutics Inc. Frequently Asked Questions

TPST is the stock ticker symbol of Tempest Therapeutics Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Jun 12 2026, market cap of Tempest Therapeutics Inc. is 18.07 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Jun 12 2026, TPST's PE ratio (Price to Earnings) is -0.42 and Price to Sales (PS) ratio is 304.81. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TPST PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Tempest Therapeutics Inc. has provided -0.613 (multiply by 100 for percentage) rate of return.